Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis
This article was originally published in Scrip
Pfizer Inc. released positive Phase III data from two induction trials testing its oral Janus kinase inhibitor Xeljanz (tofacitinib) in patients with the inflammatory bowel disease ulcerative colitis, but the company will await the results of another Phase III maintenance study before filing for an indication expansion.
You may also be interested in...
FDA Ulcerative Colitis Guidance: 'Ideal' Vision Vs. Practical Interim Approach
Agency favors assessments of signs/symptoms and endoscopy findings using well-defined and reliable patient- and clinician-reported outcomes instruments; since these don't exist, FDA will allow tweaking of existing assessment tools in the interim.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD
Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.